8-K: Pasithea Stockholders Approve Incentive Plan Boost, Reverse Split Option

Pasithea Therapeutics Corp. stockholders approved an increase in shares for its incentive plan and granted the board discretion for a reverse stock split.

Summary

• Pasithea Therapeutics Corp. held its Annual Meeting of Stockholders on September 3, 2025.
• Stockholders approved an amendment to the 2023 Stock Incentive Plan, increasing the authorized shares by 1,750,000 to a total of 2,014,221 shares.
• The board was granted discretion to effect a reverse stock split at a ratio between one-for-two (1:2) and one-for-twenty (1:20) within one year of the Annual Meeting, without further stockholder approval.
• Two Class II directors, Alfred Novak and Simon Dumesnil, were elected to serve terms expiring at the 2028 Annual Meeting.
• The appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal year 2025 was ratified.
• A quorum was present with 3,495,116 shares represented out of 7,443,577 outstanding shares entitled to vote.

Sentiment

Score: 5

Explanation: The approval of the incentive plan and director elections are standard corporate actions. However, the authorization for a reverse stock split often indicates a need to address a low stock price, which can be a negative signal. The increased share pool also presents a potential for future dilution.

Positives

• Stockholders approved an increase in the 2023 Stock Incentive Plan, allowing the company to attract and retain talent through equity awards.
• The election of directors and ratification of auditors ensures continuity in governance and financial oversight.

Negatives

• The approval of a potential reverse stock split often signals concerns about the company's stock price falling below exchange minimums, which can be perceived negatively by investors.
• Increasing the share pool for the incentive plan could lead to future dilution for existing shareholders.

Risks

• Potential for significant stock dilution from the increased share reserve under the 2023 Stock Incentive Plan.
• A reverse stock split, if implemented, may not necessarily improve the company's underlying business fundamentals or long-term stock performance, and can sometimes be followed by further price declines.
• The board has full discretion on the reverse stock split ratio (1:2 to 1:20) and timing within one year, which introduces uncertainty for investors.

Future Outlook

The company has the flexibility to issue up to 2,014,221 shares under its 2023 Stock Incentive Plan to incentivize employees and directors. The Board of Directors has the authority to implement a reverse stock split at any time within one year of the Annual Meeting, at a ratio between 1:2 and 1:20, without further stockholder approval. This suggests a potential future action to maintain Nasdaq listing compliance or improve stock perception.

Management Comments

• Tiago Reis Marques, Chief Executive Officer, signed the report.

Industry Context

NA

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution from increased incentive plan shares; uncertainty and potential impact on stock price from a future reverse stock split.
• Employees/Management: Benefit from increased equity compensation opportunities under the amended incentive plan.
• Board of Directors: Granted significant discretion regarding the implementation of a reverse stock split.

Next Steps

• The Board of Directors will determine the exact ratio and timing for a potential reverse stock split within one year of the Annual Meeting.
• The company will proceed with issuing shares under the amended 2023 Stock Incentive Plan as deemed appropriate by the Board.

Key Dates

Recommendation

The filing presents a mixed bag. While standard governance items like director elections and auditor ratification were approved, the authorization for a reverse stock split often signals underlying stock price weakness, which is a concern. The increased share pool for the incentive plan, while good for employee retention, also introduces potential dilution. Investors should hold and monitor for the board's decision on the reverse stock split and any subsequent impact on the stock price and company fundamentals.

Keywords

Pasithea Therapeutics, KTTA, SEC filing, 8-K, stock incentive plan, reverse stock split, corporate governance, annual meeting, director election, auditor ratification, stock dilution